HC Wainwright Has Bullish Forecast for VNDA Q4 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright upped their Q4 2026 EPS estimates for shares of Vanda Pharmaceuticals in a report released on Monday, January 5th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of $0.06 for the quarter, up from their prior forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

VNDA has been the subject of several other research reports. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday. Jefferies Financial Group increased their price objective on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research note on Wednesday, December 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. B. Riley boosted their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $13.63.

Vanda Pharmaceuticals Stock Up 3.3%

VNDA stock opened at $8.13 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.12 and a quick ratio of 3.10. The company has a market cap of $480.48 million, a price-to-earnings ratio of -5.73 and a beta of 0.60. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60. The company has a fifty day moving average price of $5.81 and a 200 day moving average price of $5.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The company had revenue of $56.26 million during the quarter, compared to analyst estimates of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.82%.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its position in Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares during the period. CWM LLC grew its stake in shares of Vanda Pharmaceuticals by 424.6% in the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 7,575 shares in the last quarter. PVG Asset Management Corp acquired a new position in shares of Vanda Pharmaceuticals during the first quarter valued at $48,000. Quarry LP acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $53,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the third quarter valued at about $72,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.